Log2Lose: Incenting Weight Loss and Dietary Self-monitoring in Real-time to Improve Weight Management Among Adults With Obesity
5 other identifiers
interventional
706
1 country
2
Brief Summary
This study involves an evaluation of whether providing small incentives weekly for dietary self-monitoring and/or weight loss improves short- and long-term weight loss. Participants can expect to be on study for 18 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable obesity
Started May 2021
Longer than P75 for not_applicable obesity
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 22, 2021
CompletedFirst Posted
Study publicly available on registry
February 25, 2021
CompletedStudy Start
First participant enrolled
May 13, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 8, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 10, 2025
CompletedResults Posted
Study results publicly available
May 20, 2026
CompletedMay 20, 2026
April 1, 2026
2.9 years
February 22, 2021
March 30, 2026
April 27, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 26 Weeks
Measured on a calibrated, digital scale to the nearest 0.1 kg
26 weeks
Secondary Outcomes (6)
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 52 Weeks
52 weeks
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 78 Weeks
78 weeks
Change in Use of Cardiovascular Medications From Baseline to 78 Weeks for All Participants
Baseline, 78 weeks
Change in Use of Cardiovascular Medications From Participants Who Took 1 or More Medications From Baseline to 78 Weeks
Baseline, 78 weeks
Diastolic Blood Pressure
baseline, 26, 52, and 78 weeks
- +1 more secondary outcomes
Other Outcomes (2)
Intrinsic Motivation for Weight Loss as Assessed by Modified Treatment Self-Regulation Questionnaire
26 weeks
Extrinsic Motivation for Weight Loss as Assessed by Modified Treatment Self-Regulation Questionnaire
26 weeks
Study Arms (4)
Combined
EXPERIMENTALWeekly incentives for dietary self-monitoring and weight loss
Dietary self-monitoring
EXPERIMENTALWeekly incentives for dietary self-monitoring
Weight loss
EXPERIMENTALWeekly incentives for weight loss
Control
NO INTERVENTIONInterventions
Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
Participants can earn up to $300 during the trial for achieving weight loss
Eligibility Criteria
You may qualify if:
- BMI ≥30 kg/m2
- Desire to lose weight
- Agrees to attend outcome visits per protocol
- Available for class times
- Transportation and ability to attend in-person study visits at baseline (screening), 26, 52, and 78 weeks
- Able to stand for weight measurements without assistance
- Able to speak and read English
- Able to download and use the MyFitnessPal and Fitbit apps daily
- Possess smart phone with data and texting plan
- Have or willing to create a Gmail address
- Able to connect to a video conference call using a smartphone, tablet or computer with a webcam and microphone
- Score of at least 4 out of 6 on a validated cognitive screener
You may not qualify if:
- Weight \>380 lb
- Weight loss of at least 10 lbs in the month prior to screening
- Currently enrolled or enrolled in previous month in a clinical, research, or community program focusing on lifestyle change that could affect weight
- Current use of weight loss medication
- History of bariatric surgery or planning to have bariatric surgery in the study timeframe
- Residing in a nursing home or receiving home health care
- Impaired hearing
- Significant dementia, drug or alcohol misuse, or unstable psychiatric illness (e.g., schizophrenia, psychosis)
- Current treatment for cancer or being treated for cancer (besides basal cell carcinoma or squamous cell) in the last 6 months
- Use of insulin, sulfonylureas, or meglitinides due to increased risk for hypoglycemia
- Pregnant, breastfeeding, or planning to become pregnant within the study timeframe
- Diuretic medication doses higher than hydrochlorothiazide 25 mg daily, furosemide 40 mg daily, torsemide 20 mg daily, bumetanide 1 mg daily, or any use of metolazone; use of potassium-sparing diuretics is acceptable
- Chronic kidney disease at stage 4 or 5
- Unstable heart disease in the 6 months prior to screening
- Exertional chest pain
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Wisconsin, Madisonlead
- Duke Universitycollaborator
- National Heart, Lung, and Blood Institute (NHLBI)collaborator
Study Sites (2)
Duke University Medical Center
Durham, North Carolina, 27705, United States
University of Wisconsin-Madison
Madison, Wisconsin, 53705, United States
Related Publications (2)
Shaw RJ, Miller H, Barnes C, Davenport C, Morton-Oswald S, Jackson S, Bean M, Cohen J, Griffin C, Pendergast J, Olsen M, Gierisch J, Voils C. Development, Challenges, and Evolution of the Log2Lose Intervention for Weight Management: Randomized Controlled Digital Health Trial. JMIR Form Res. 2025 Nov 17;9:e70842. doi: 10.2196/70842.
PMID: 41248493DERIVEDVoils CI, Gierisch JM, Pendergast JF, Davenport CA, Olsen MK, Barnes C, Bean M, Cadmus-Bertram L, Colon J, Elwert F, Garza K, Gavin KL, Jackson S, Miller H, Morton-Oswald S, Pabich S, Reed SD, Yancy WS Jr, Shaw RJ. Study protocol for Log2Lose: A randomized controlled trial to evaluate financial incentives for dietary self-monitoring and interim weight loss in adults with obesity. Contemp Clin Trials. 2025 Sep;156:108042. doi: 10.1016/j.cct.2025.108042. Epub 2025 Aug 5.
PMID: 40774423DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Corrine I. Voils, PhD
- Organization
- University of Utah Department of Internal Medicine
Study Officials
- PRINCIPAL INVESTIGATOR
Lisa Cadmus-Bertram, PhD
University of Wisconsin, Madison
- PRINCIPAL INVESTIGATOR
Corrine Voils, PhD
University of Utah Department of Internal Medicine
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 22, 2021
First Posted
February 25, 2021
Study Start
May 13, 2021
Primary Completion
April 8, 2024
Study Completion
April 10, 2025
Last Updated
May 20, 2026
Results First Posted
May 20, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF
- Time Frame
- Study data will be made available for use by investigators not associated with the proposed study within three years after the primary results have been published.
- Access Criteria
- 1. The data will be used for research or implementation purposes and not to identify individual participants 2. The data must be secured using the appropriate computer technology 3. The data must be destroyed or returned after analyses are complete 4. The authors of any manuscript resulting from the Log2Lose data must acknowledge the source of the data upon which their manuscript is based. 5. Any analyses for the purpose of presentation, abstracts, and/or publications must be coordinated with the Log2Lose leadership team, so there can be some coordination of analyses to ensure that redundant analyses are not being performed independently 6. All coauthors must be given an opportunity for review and approval of a draft manuscript prior to submission for publication.
First, investigators will strip all data of personal identifiers (i.e., personal health information (PHI)) in accordance with the HIPAA privacy rule. Each consented and enrolled participant will be assigned a unique study ID, which will be the only participant-level identifier. Time information starting at baseline will be coded in units of study time, with baseline = '0' and termination of 18 months or dropout for all participants, regardless of the calendar date of their baseline visit. Proprietary software code will be shared in accordance with institutional policies and consent of the creators.